34
2
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T16560 | Poloxin | PLK | |
Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM). | |||
T3643 | HMN-176 | PLK | |
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1). | |||
T6282 | GSK461364 | GSK461364A | PLK |
GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3. | |||
T15454 | GW843682X | GW843682 | VEGFR , PLK , CDK , PDGFR , Aurora Kinase |
GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM). | |||
T10215 | AAPK-25 | Apoptosis , PLK , Aurora Kinase | |
AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in prometaphase, followed by a surge in apoptosis. AAPK-25 targets Aurora-A/-B/-C with ... | |||
T14927 | Centrinone | LCR-263 | PLK , Aurora Kinase |
Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM). | |||
T1839 | Mps1-IN-2 | Kinesin , PLK | |
Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor. | |||
T2634 | Ro3280 | RO 3280,Ro5203280 | PLK |
Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM). | |||
T2704 | MLN0905 | PLK1 Inhibitor | PLK |
MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM). | |||
T7200 | TAK-960 | PLK | |
TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively. | |||
T6217 | LFM-A13 | PLK , JAK , BTK | |
LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK. | |||
T16750 | Rigosertib | ON-01910 | Apoptosis , FLT , PLK , PI3K , Bcr-Abl , CDK , PDGFR , Src |
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition of the PI3 kina... | |||
T21678 | 3MB-PP1 | PLK | |
3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifi... | |||
T2438 | HMN-214 | IVX-214,HMN214 | PLK |
HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM. | |||
T5818 | Rigosertib sodium | Rigosertib,Estybon,ON-01910 | Apoptosis , PLK , PI3K |
Rigosertib sodium (ON-01910), a non-ATP-competitive inhibitor of PLK1(IC50=9 nM), exhibits 30-fold higher specificity activity over Plk2 and no effect on Plk3. | |||
T6247 | Onvansertib | NMS-P937,NMS-1286937 | Apoptosis , PLK |
Onvansertib (NMS-1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3. | |||
T19664 | ON1231320 | GBO-006 | Apoptosis , PLK |
ON1231320 (GBO-006) is a Polo-like kinase 2 (PLK2) inhibitor. | |||
T2271 | SBE13 Hydrochloride | SBE 13 hydrochloride,SBE 13 HCl | Apoptosis , PLK , Autophagy |
SBE13 Hydrochloride (SBE 13 HCl) is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3. | |||
T22288 | (1E)-CFI-400437 dihydrochloride | CFI-400437 dihydrochloride | PLK |
(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor. | |||
T6019 | Volasertib | BI 6727 | Apoptosis , PLK |
Volasertib (BI 6727) (BI-6727) is a potent inhibitor of PLK1 (IC50: 0.87 nM), inducing mitotic arrest and apoptosis. It also inhibits PLK2/PLK3 (IC50s: 5/56 nM). | |||
T6283 | Wortmannin | SL-2052,KY-12420 | ATM/ATR , DNA-PK , Serine/threonin kinase , PLK , PI3K , Antibiotic , Autophagy |
Wortmannin (SL-2052) is a PI3K inhibitor (IC50=3 nM) that is covalent and irreversible. Wortmannin is also an inhibitor of PlK1 and PlK3 (IC50=5.8/48 nM) that blocks autophagy. | |||
T6173 | BI 2536 | Apoptosis , Epigenetic Reader Domain , PLK | |
BI2536 is an effective Plk1 inhibitor (IC50: 0.83 nM). It has 4- and 11-fold greater selectivity than Plk2 and Plk3. | |||
T40265 | PLK1-IN-2 | PLK1-IN-2 | |
PLK1-IN-2 is a PLK1 kinase inhibitor with an IC 50 value of 0.384 μM. | |||
T63886 | PLK1-IN-4 | ||
PLK1-IN-4 is a potent and selective inhibitor of PLK1 (IC50<0.508 nM). PLK1-IN-4 exhibits broad anti-proliferative effects on a wide range of cancer cells. PLK1-IN-4 is able to block the cell cycle in G2/M phase and indu... | |||
T74777 | PLK1-IN-6 | ||
PLK1-IN-6, a potent and selective inhibitor of PLK1, demonstrates significant anti-proliferative activities against cancer cells with an IC50 value of 0.45 nM [1]. | |||
T64058 | PLK1/BRD4-IN-1 | ||
PLK1/BRD4-IN-1 (9b) is an orally active dual inhibitor of PLK1 (IC50: 22 nM) and BRD4 (IC50: 109 nM). It has been shown to have good anti-tumour effects in vivo. | |||
T71718 | Plk1 PBD-IN-143 | ||
Plk1 PBD-IN-143 is a novel Inhibitor of the Polo-Box Domain of Polo-like Kinase 1 (Plk1 PBD). | |||
T81441 | PLK1/p38γ-IN-1 | p38 MAPK | |
PLK1/p38γ-IN-1 (compound 14) serves as a dual inhibitor targeting both PLK1 and p38γ kinases, effectively suppressing the proliferation of human hepatocellular carcinoma and hepatoblastoma cell lines in vitro [1]. | |||
T81440 | PLK1-IN-7 | ||
PLK1-IN-7 (compound 30e) is a potent inhibitor exhibiting an IC50 value of 0.66 nM and demonstrates significant antiproliferative and antitumor activities [1]. | |||
T27853 | LS-008 | LS 008,LS008 | |
LS-008, a PLK/PI3K dual inhibitor, may be used for treating cancer. | |||
T40507 | BTO-1 | ||
BTO-1 is a compound known as a Polo-like kinase (Plk) inhibitor, commonly employed for its effectiveness in regulating processes involving phosphorylation and dephosphorylation. | |||
T69296 | PHA-680626 | ||
PHA-680626 is a potent and selective PLK inhibitor. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of bot... | |||
T73449 | CZS-241 | ||
CZS-241 is an orally active, selective Polo-like Kinase (PLK) 4 inhibitor with an IC 50 of 2.6 nM that also inhibits TRKA at an IC 50 of 2.74 μM. It induces apoptosis and causes cell cycle arrest at the S/G2 phase, demon... | |||
T24652 | Poloppin | ||
Poloppin is a protein-protein interactions modulator of the mitotic polo-like kinases that acts by targeting mutant KRAS. It works synergistically with Crizotinib, an inhibitor of the c-MET receptor, against mutant KRAS-... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04376 | PLK1 Protein, Human, Recombinant (His) | Human | Baculovirus-Insect Cells |
Serine / threonine-protein kinase PLK1 / PLK-1, also known as polo-like kinase 1 (PLK-1) or serine / threonine-protein kinase 13 (STPK13), Polo-like kinases (PLKs), is a family of four serine / threonine protein kinases ... | |||
TMPY-04438 | PLK1 Protein, Mouse, Recombinant (His) | Mouse | Baculovirus-Insect Cells |
Serine / threonine-protein kinase PLK1 / PLK-1, also known as polo-like kinase 1 (PLK-1) or serine / threonine-protein kinase 13 (STPK13), Polo-like kinases (PLKs), is a family of four serine / threonine protein kinases ... |